Stock Ticker

  • Loading stock data...

Pharmacyte Biotech Inc (OTCMKTS:PMCB) Progresses With Patients Enrollment Process In Pancreatic Cancer Clinical Trial

Pharmacyte Biotech Inc (OTCMKTS:PMCB) is successfully making progress with its enrollments process in a pivotal clinic trial targeting advanced, inoperable pancreatic cancer. It started with the enrollment after the FDA approved its pre-IND request meeting. A host of oncologists, clinicians and renowned scientists will discuss with the U.S. regulatory agency on the related study and […]

Pharmacyte Biotech Inc (OTCMKTS:PMCB) CEO Explains Cell-in-a-Box Technology

Pharmacyte Biotech Inc (OTCMKTS:PMCB) published an educational piece of article to help people learn about the Cell-in-a-Box technology and its role in treatment of pancreatic cancer. The first article is written by the CEO Dr. Gerald W. Crabtree. The company’s live-cell encapsulation technology, termed as “Cell-in-a-Box®”, does not deliver and encapsulate drugs to cure pancreatic […]

Pharmacyte Biotech Inc (OTCMKTS:PMCB) Announces Major Milestones Right Before Phase 2b Clinical Trial in Pancreatic Cancer Starts

Pharmacyte Biotech Inc (OTCMKTS:PMCB) is about to start the phase 2b clinical trial in pancreatic cancer. Before it initiates, the company wants its investors and customers to know some of the major milestones it’s working on and craves to attain down the line. Milestones Some of the major steps that Pharmacyte intends to take are […]

Pharmacyte Biotech Inc (OTCMKTS:PMCB) To Design Clinical Protocol (NAII, ULUR)

Pharmacyte Biotech Inc (OTCMKTS:PMCB) announced the list of major milestone tasks that it plans to achieve before it begins its Phase IIB trial in pancreatic cancer. The company stated it will have a clinical protocol that will be designed in coordination with Contract Research Organization and its team of oncologists. This designed protocol can be […]

Pharmacyte Biotech Inc (OTCMKTS:PMCB) To Establish IND Team (NPHC,ULUR)

Providing updates on objectives, Pharmacyte Biotech Inc (OTCMKTS:PMCB) reported that it will form an IND team to design the IND and assess it before being officially filed with the regulatory authorities. He company’s IND Team will include a Project Manager, a Medical Officer, a Statistician, a Chemistry, Controls and Manufacturing Expert, a Pharmacologist, a Pharmakineticist, […]

Pharmacyte Biotech Inc (OTCMKTS:PMCB) Fails To Move Up (NPHC, GBLX)

Pharmacyte Biotech Inc (OTCMKTS:PMCB) highlighted major goals that need to be met in order to begin Phase 2b study for pancreatic cancer treatment. This study will examine the safety and efficacy of designed pancreatic cancer treatment. The therapy is a well-planned combination of microcapsules comprising genetically modified live cells and ifosfamide dosage. Pharmacyte revealed that […]

Pharmacyte Biotech Inc (OTCMKTS:PMCB) Updates On Interim Audit Completion Of cGMP Facility

Pharmacyte Biotech Inc (OTCMKTS:PMCB) stated that it has completed the interim audit of cGMP facility. The company will acquire the cell-in-a-box capsules for the clinical trials from the same facility. Austrianova’s Chief Technical Officer, Professor Walter H. Günzburg, stated that they are pleased to report that there were no major issues during the inspection process. […]

Pharmacyte Biotech Inc (OTCMKTS:PMCB), Uluru Inc (OTCMKTS:ULUR) And Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) Declines Over 5%

Pharmacyte Biotech Inc (OTCMKTS:PMCB) updated on the process of the compliance process completion of the Austrianova’s current Good Manufacturing Practices-compliant facility in Thailand. The encapsulation process of genetically modified human cells in the unique Cell-in-a-Box® capsules will be carried out in this facility. This are the same capsules that the company intends to use in […]

Can Pharmacyte Biotech Inc (OTCMKTS:PMCB) Move Up On The Chart?

In last trading session, the stock price of Pharmacyte Biotech Inc (OTCMKTS:PMCB) declined 0.52% to close the week at $0.0959. The decline came at a share volume of 1.06 million compared to monthly average share volume of 1.52 million. Pharmacyte stock has been stuck in a low trading session from last few trading sessions. Recently, […]

Pharmacyte Biotech Inc (OTCMKTS:PMCB) And Growblox Sciences Inc (OTCMKTS:GBLX) Trades In A Narrow Range

Pharmacyte Biotech Inc (OTCMKTS:PMCB) declined 0.52% and closed at $0.0959 in last trading session. The biotech firm is still in clinical stage and it is working to develop targeted therapies to treat diabetes and cancer based on Cell-in-a-Box® technology. Recently, the COO of Pharmacyte, Dr. Gerald W. Crabtree, Ph.D. highlighted company’s development plans in an […]

Pharmacyte Biotech Inc (OTCMKTS:PMCB) COO Features In PharmaVOICE Magazine ( NPHC, RELV)

Pharmacyte Biotech Inc (OTCMKTS:PMCB) a biotech firm in clinical stage developing targeted treatments for diabetes and cancer using its patented Cell-in-a-Box® technology reported that Dr. Gerald W. Crabtree, Ph.D., the Chief Operating Officer, has been featured in the PharmaVOICE Magazine, September edition. The COO said that they involved thought leaders in both the diabetes and […]

Pharmacyte Biotech Inc (OTCMKTS:PMCB) CEO Features In ‘PharmaVOICE’ (SBOTF, HAIR)

Pharmacyte Biotech Inc (OTCMKTS:PMCB) reported that its COO Dr. Gerald W. Crabtree, Ph.D., and CEO, Mr. Kenneth L. Waggoner, JD have been featured in the September edition of PharmaVOICE Magazine. Waggoner, the CEO said that they are relying greatly on the advice of the three world known physicians in oncology in developing of upcoming clinical […]

Sign Up To Get Our Latest Stocks Alerts